| Biomarker ID | 1309 |
| PMID | 24411283 |
| Year | 2014 |
| Biomarker | PDLIM5 [SNP: rs17021918] |
| Biomarker Basis | Mutation Based |
| Biomolecule | Mutation |
| Source | Blood |
| Subjects | Humans |
| Regulation | Decreased risk of PCa Specific Mortality |
| Odds Ratio/Hazard Ratio/Relative Risk | HR: 0.89 (95% CI: 0.81–0.97) |
| Effect on Pathways | Pathways include: ALPK3 human kinase ARCHS4 coexpression, ALPK2 human kinase ARCHS4 coexpression, MYLK4 human kinase ARCHS4 coexpression, HIPK3 human kinase ARCHS4 coexpression, NEK7 human kinase ARCHS4 coexpression |
| Experiment | PCa Specific Mortality Vs No Mortality |
| Type of Biomarker | Prognostic |
| Cohort | 8 different cohorts from The Breast and Prostate Cancer Cohort Consortium were studied in this analysis. Overall 10487 cases were included out of which 1053 had PCa related deaths |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.01 |
| Method Used | NA |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |